Ticker: MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biopharmaceutical company focused on addressing metabolic dysfunction-associated steatohepatitis (MASH) through its FDA-approved product, Rezdiffra. As of June 30, 2025, the company has faced both notable successes and challenges. Below is an ove...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has released its quarterly report for the period ending March 31, 2025, which presents a mixed picture of the company's financial health and operational activities. Key Highlights: Product Revenue: Recorded at $137.25 million for Q1 2025, marking sig...